Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation

Fan Liao
Aimin Li
Monica Xiong
Hong Jiang
Mary Beth Finn

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
Authors
Fan Liao, Aimin Li, Monica Xiong, Hong Jiang, Mary Beth Finn, Rosa Hoyle, Jennifer Keyser, Katheryn B Lefton, Grace O Robinson, Javier Remolina Serrano, Cheryl Eg Leyns, Gilbert Gallardo, Jason D Ulrich, David M Holtzman, and et al
Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation

Fan Liao,1 Aimin Li,1 Monica Xiong,1 Nga Bien-Ly,1 Hong Jiang,1 Yin Zhang,2 Mary Beth Finn,1 Rosa Hoyle,1 Jennifer Keyser,1 Katheryn B. Lefton,1 Grace O. Robinson,1 Javier Remolina Serrano,1 Adam P. Silverman,2 Jing L. Guo,1 Jennifer Getz,1 Kirk Henne,2 Cheryl E.G. Leyns,1 Gilbert Gallardo,1 Jason D. Ulrich,1 Patrick M. Sullivan,3 Eli Paul Lerner,4 Eloise Hudry,4 Zachary K. Sweeney,2 Mark S. Dennis,3 Bradley T. Hyman,1 Ryan J. Watts,2 and David M. Holtzman1

1Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA. 2Denali Therapeutics Inc., South San Francisco, California, USA. 3Department of Medicine, Duke University, Durham, North Carolina, USA. 4MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.

Previous work has suggested that apoE influences Alzheimer disease (AD) by affecting amyloid ß (Aß) aggregation and clearance; however, the molecular mechanism underlying these findings remains largely unknown. Herein, we tested whether anti–human apoE antibodies can decrease Aß pathology in mice producing both human apoE and APOE4, and investigated the mechanism underlying these effects. We utilized APPPS1-21 mice crossed to apoE4-knockin mice expressing human apoE4 (APPPS1-21/APOE4). We discovered an anti–human apoE antibody, anti–human apoE 4 (HAE-4), that specifically recognizes human apoE4 and apoE3 and preferentially binds nonlipidated, aggregated apoE over the lipidated apoE found in circulation. HAE-4 also binds to apoE in amyloid plaques in unfixed brain sections and in vivo. When delivered centrally or by peripheral injection, HAE-4 reduced Aß deposition in APPPS1-21/APOE4 mice. Using adeno-associated virus to express 2 different full-length anti–apoE antibodies in the brain, we found that HAE antibodies decreased amyloid accumulation, which was dependent on Fcy receptor function. These data support the hypothesis that a primary mechanism for apoE-mediated plaque formation may be a result of apoE aggregation, as preferentially targeting apoE aggregates with therapeutic antibodies reduces Aß pathology and may represent a selective approach to treat AD.

The apolipoprotein E E4 allele of the APOE gene is the strongest genetic factor for late-onset Alzheimer disease (LOAD). There is compelling evidence that apoE influences Alzheimer disease (AD) in large part by affecting amyloid ß (Aß) aggregation and clearance; however, the mechanism underlying these findings remains largely unknown. Herein, we tested whether anti–human apoE antibodies can decrease Aß pathology in mice producing both human apoE and APOE4, and investigated the mechanism underlying these effects. We utilized APPPS1-21 mice crossed to apoE4-knockin mice expressing human apoE4 (APPPS1-21/APOE4). We discovered an anti–human apoE antibody, anti–human apoE 4 (HAE-4), that specifically recognizes human apoE4 and apoE3 and preferentially binds nonlipidated, aggregated apoE over the lipidated apoE found in circulation. HAE-4 also binds to apoE in amyloid plaques in unfixed brain sections and in vivo. When delivered centrally or by peripheral injection, HAE-4 reduced Aß deposition in APPPS1-21/APOE4 mice. Using adeno-associated virus to express 2 different full-length anti–apoE antibodies in the brain, we found that HAE antibodies decreased amyloid accumulation, which was dependent on Fcy receptor function. These data support the hypothesis that a primary mechanism for apoE-mediated plaque formation may be a result of apoE aggregation, as preferentially targeting apoE aggregates with therapeutic antibodies reduces Aß pathology and may represent a selective approach to treat AD.

Introduction

Alzheimer disease (AD) is the most common form of dementia and it affects more than 5 million people in the United States (www.alz.org). Compelling evidence has shown that amyloid ß (Aß) plays a key role in the pathogenesis of AD (1, 2). In autosomal dominant AD, missense mutations in amyloid precursor protein (APP) or components of the ß-secretase complex presenilin 1 (PS1) or presenilin 2 (PS2) result in early onset amyloid deposition in the brain due to a relative increase in production of longer Aß species such as Aß42, an increase in all Aß species, or an alteration of Aß aggregation propensity and clearance (3). Also, a protective mutation in AD was recently described near the N-terminus of the ß secretase site in APP that results in decreased Aß production (4).

The majority of AD cases are known as late-onset AD (LOAD), which clinically begins after the age of 65. The apolipoprotein E (APOE) gene is the strongest genetic risk factor for LOAD. In humans, the 3 common isoforms of apoE — E2, E3, and E4 — are encoded by a 299 amino acid protein. Compared with the most common form of apoE, apoE3 (Cys112, Arg158), each allele of apoE4 (Arg112, Arg158) strongly increase the risk for AD (~3.7-fold for one E4 allele and -12-fold for 2 E4 alleles relative to the E3/E3 genotype); in contrast, apoE2 (Cys112, Cys158) is protective for AD (5, 6). How apoE impacts AD pathogenesis is not entirely clear; however, evidence shows that apoE influences Aß aggregation and clearance (7) and is also found in amyloid plaques (8, 9).

Previously, our group has shown that passive immunotherapy using HJ6.3, an antibody targeting endogenous murine apoE, strongly suppresses Aß pathology in the APPswe/PS1ΔE9 mouse brain when treatment is started prior to plaque onset (10). When administered after plaque onset, HJ6.3 reduced brain Aß plaque load, restored resting-state functional connectivity, and mildly improved spatial performance in the water maze (11). However, in order to further explore whether such an approach could potentially translate into an immunotherapy for humans, studies with apoE antibodies targeting human apoE in animals expressing human Aß and apoE are critical. It is also important to understand the mechanism(s) underlying the therapeutic effects.

Related Commentary: p. 1734

Authorship note: FL and AL contributed equally to this work.

Conflict of interest: NBL, YZ, APS, JLG, KH, ZS, MSD, and RW are employees of Denali. FL, HJ, and DMH are inventors on a patent filed by Washington University on the topic of anti–apoE antibodies that was licensed by Denali. DMH cofounded and is on the scientific advisory board of C2N Diagnostics. DMH consults for Genentech, AbbVie, Eli Lilly, Proclara, and Denali. Washington University receives research grants to the lab of DMH from C2N Diagnostics, Eli Lilly, AbbVie, and Denali.

Submitted: July 20, 2017; Accepted: February 1, 2018.

In the present study, we tested the effects of anti–human apoE (HAE) antibodies, a new series of apoE antibodies targeting human apoE, on Aβ pathology in APPPS1-21/APOE4-knockin (KI) mice. These mice were generated by crossing human apoE4-KI mice expressing human apoE4 under the control of endogenous murine apoE regulatory elements (APOE4) to APPPS1-21 (13). We found that HAE-4, an antibody specific for apoE3 and apoE4, was able to reduce Aβ deposition when infused directly into the brain, delivered by i.p. injection starting at the time of plaque onset, or expressed in the brain via adeno-associated virus–mediated (AAV–mediated) delivery. Here we present in detail the features of antibody HAE-4 that facilitate its ability to decrease Aβ deposition and propose a likely mechanism of action.

Results
Characterization of the HAE series of apoE antibodies using recombinant human apoE. We used a direct ELISA to test whether the HAE series of apoE antibodies binds to different recombinant apoE isoforms (Figure 1, A–D). HAE-2 and HAE-3 recognized all 3 isoforms of human apoE (Figure 1, B and C), whereas HAE-4 had much higher affinity for apoE3 and apoE4 with no appreciable binding to apoE2 (Figure 1D). HAE-1 was apoE4-specific (Figure 1A). Using surface plasmon resonance (SPR) (Figure 1, E–G), the apparent $K_D$ values were determined for HAE-1 ($6.02 \times 10^{-8}$ M), HAE-2 ($3.19 \times 10^{-10}$ M), and HAE-4 ($1.98 \times 10^{-7}$ M) for their interaction with recombinant apoE4 (Table 1). The $K_D$ value for HAE-3 was not determined because it showed binding characteristics similar to those of HAE-2 in ELISA (Figure 1, B and C). Oddly, the maximum response units for HAE-1 and HAE-4 as measured by SPR were only 10% of the maximum value seen for HAE-2, despite greater apoE4 capture levels for experiments with HAE-1 and HAE-4. This suggested the possibility that these 2 antibodies were recognizing a minor fraction of the immobilized apoE, a hypothesis that was later validated (see below).

Effects of intracerebroventricularly administered anti–apoE antibodies on Aβ pathology in APPPS1-21/APOE4 mice. apoE is present in Aβ-containing amyloid plaques in both human AD as well as in mouse models of amyloidosis (8, 9, 14). To test whether HAE antibodies are able to decrease Aβ pathology in APPPS1-21/APOE4 mice, we directly infused the antibodies into the lateral ventricle of the mice before plaque onset, starting at the age of 2 months. Antibodies were infused continuously (0.3 µg/h) via an osmotic pump for 6 weeks and mice were assessed at the age of 3.5 months (females, n = 10–11 per group). Infusions of PBS or a control mouse IgG2ab into the mouse brain were included as negative controls, and anti–Aβ antibody HJ5.1 (15) was used as a positive control. Aβ plaques were stained using anti–Aβ antibody HJ3.4 (Supplemental Figure 1A; supplemental material available online with this article;
Effects of peripheral administration of anti–apoE antibodies on Aβ pathology in APPPS1-21/APOE4 mice. Because i.c.v.-administered HAE-1 and HAE-4 significantly reduced Aβ plaque load compared with PBS (Supplemental Figure 1A), HAE-4 also significantly reduced Aβ plaque load compared with PBS (Supplemental Figure 1A). Some of the antibodies tended to decrease fibrillar Aβ and insoluble Aβ40 and Aβ42, but the effects were not statistically significant (Supplemental Figure 1, B–D).

Effects of peripheral administration of anti–apoE antibodies on Aβ pathology in APPPS1-21/APOE4 mice. Because i.c.v.-administered HAE-1 and HAE-4 significantly reduced the Aβ plaque load in APPPS1-21/APOE4 mice, we tested whether peripheral administration of HAE-1 and HAE-4 could impact Aβ pathology in these mice. Beginning at the age of 2 months, APPPS1-21/APOE4 mice (females, n = 10–13/group) were treated weekly with i.p. injections of 50 mg/kg body weight of antibodies until 3.5 months of age. A group of untreated mice were harvested at 2 months to determine baseline Aβ pathology. As determined by Aβ immunostaining, HAE-4 significantly reduced Aβ plaque load compared with PBS (Supplemental Figure 1A). Some of the antibodies tended to decrease fibrillar Aβ and insoluble Aβ40 and Aβ42, but the effects were not statistically significant (Supplemental Figure 1, B–D).

Because i.c.v.-administered HAE-1 and HAE-4 significantly reduced the Aβ plaque load in APPPS1-21/APOE4 mice, we tested whether peripheral administration of HAE-1 and HAE-4 could impact Aβ pathology in these mice. Beginning at the age of 2 months, APPPS1-21/APOE4 mice (females, n = 10–13/group) were treated weekly with i.p. injections of 50 mg/kg body weight of antibodies until 3.5 months of age. A group of untreated mice were harvested at 2 months to determine baseline Aβ pathology. As determined by Aβ immunostaining, HAE-4 significantly reduced Aβ plaque load compared with PBS (Supplemental Figure 1A). Some of the antibodies tended to decrease fibrillar Aβ and insoluble Aβ40 and Aβ42, but the effects were not statistically significant (Supplemental Figure 1, B–D).

Figure 2. Effects of intraperitoneally administered anti–apoE antibodies on amyloid pathology in APPPS1-21/APOE4 mice. At the age of 2 months, the mice were injected i.p. weekly with 50 mg/kg antibodies (all female, n = 10–13/group). The mice were sacrificed at the age of 3.5 months and the Aβ pathology in the brain was assessed using histology and biochemical approaches. (A) Representative Aβ staining using HJ3.4 (left panel) and representative X-34 staining for fibrillar plaques (right panel). Scale bar = 1 mm. (B) Quantification of HJ3.4 staining. (C) Quantification of X-34 staining. (D) Aβ40 and (E) Aβ42 was measured by ELISA in insoluble fractions of tissue lysates (Guan = Guanidine) by ELISA. One-way ANOVA followed by Tukey’s t test was performed to compare different groups shown in B–E. Data are mean ± SEM. *P < 0.05, **P < 0.01.
At 2 months of age, the mice (mixed sexual phenotype, \( n = 17–18 \)) received weekly i.p. injections of control IgG2ab (50 mg/kg), anti–A\(\beta\) antibody HJ3.4, which recognizes amyloid plaques (50 mg/kg), or HAE-4 (2, 10, and 50 mg/kg) for 2.5 months prior to sacrifice. There was a significant dose-dependent effect of HAE-4 on reducing insoluble A\(\beta\)40 and A\(\beta\)42 levels in the brain (Supplemental Figure 4).

Binding profile of HAE-1, HAE-2, and HAE-4 with lipidated apoE. (A and B) Antibody binding to mouse plasma from EKO, APOE2, APOE3, and APOE4 mice was coated onto the plates. Titrations of chi–HAE-2 and chi–HAE-4 were incubated and antibody that was captured was detected with HRP-goat anti–human IgG antibody. (C and D) HAE-2 or HAE-4 was immobilized on the plate followed by the addition of plasma from mice with different genotypes. apoE, captured from the plasma, was detected with HRP-goat polyclonal anti–apoE. (E) Plasma inhibition of anti–apoE binding to immobilized recombinant apoE4. HAE-1 (50 nM), HAE-2 (4 nM), and HAE-4 (50 nM) were preincubated with serially diluted plasma from APOE4-KI mice and then added to plates coated with recombinant apoE4. The HAE antibodies bound to the plates were detected with HRP-goat anti–mouse IgG antibodies. (F) Plasma antibody concentrations of HAE-4 or control IgG following i.p. injection into APOE4-KI or EKO mice. HAE-4 was dosed at 2 mg/kg, 10 mg/kg, and 50 mg/kg and plasma samples were collected by submandibular puncture. Control murine IgG2a (msIgG2a) was anti-Her2 and dosed at 10 mg/kg. Quantification of dosed antibodies in plasma was by antigen-capture ELISA using coated recombinant apoE4 to detect HAE-4, with recombinant Her2 used to detect the control IgG.

Figure 3. Binding profile of HAE-1, HAE-2, and HAE-4 with lipidated apoE. (A and B) Antibody binding to mouse plasma from EKO, APOE2, APOE3, and APOE4 mice was coated onto the plates. Titrations of chi–HAE-2 and chi–HAE-4 were incubated and antibody that was captured was detected with HRP-goat anti–human IgG antibody. (C and D) HAE-2 or HAE-4 was immobilized on the plate followed by the addition of plasma from mice with different genotypes. apoE, captured from the plasma, was detected with HRP-goat polyclonal anti–apoE. (E) Plasma inhibition of anti–apoE binding to immobilized recombinant apoE4. HAE-1 (50 nM), HAE-2 (4 nM), and HAE-4 (50 nM) were preincubated with serially diluted plasma from APOE4-KI mice and then added to plates coated with recombinant apoE4. The HAE antibodies bound to the plates were detected with HRP-goat anti–mouse IgG antibodies. (F) Plasma antibody concentrations of HAE-4 or control IgG following i.p. injection into APOE4-KI or EKO mice. HAE-4 was dosed at 2 mg/kg, 10 mg/kg, and 50 mg/kg and plasma samples were collected by submandibular puncture. Control murine IgG2a (msIgG2a) was anti-Her2 and dosed at 10 mg/kg. Quantification of dosed antibodies in plasma was by antigen-capture ELISA using coated recombinant apoE4 to detect HAE-4, with recombinant Her2 used to detect the control IgG.

Cant changes in levels of brain apoE, plasma apoE, or plasma A\(\beta\) after HAE-1 or HAE-4 treatment relative to the control groups at the same age (Supplemental Figure 2). A possible reason that the i.p. injection of 50 mg/kg HAE-4 had a somewhat greater effect on reducing A\(\beta\) levels than the results obtained with chronic i.c.v. infusion (Supplemental Figure 1) is that the concentration of HAE-4 in the brain after 6 weeks of treatment was significantly higher with the i.p. injection paradigm (6.37 ± 2.05 ng/100 mg tissue, \( n = 13 \)) than the i.c.v. infusion paradigm (2.16 ± 0.7 ng/100 mg tissue, \( n = 9 \)) (\( P = 0.001 \)). Unlike HAE-4, HAE-1 had no significant effect on lowering A\(\beta\) levels. This may be due to the fact that HAE-1 is an IgG1 antibody whereas HAE-4 is an IgG2ab antibody. Mouse IgG1 antibodies bind poorly to Fc\(\gamma\)R1 receptors (16). In a separate experiment performed under the same conditions, HAE-3 did not change the A\(\beta\) plaque load, fibrillar plaque load, or insoluble A\(\beta\) in the brain compared with PBS-treated mice (Supplemental Figure 3). This is likely due to the very short half-life of HAE-3 in the blood following i.p. injection (see below). In another cohort of APPPS1-21/APOE4 animals, we performed a dose-response study with HAE-4. At 2 months of age, the mice (mixed sexual phenotype, \( n = 17–18 \)) received weekly i.p. injections of control IgG2ab (50 mg/kg), anti–A\(\beta\) antibody HJ3.4, which recognizes amyloid plaques (50 mg/kg), or HAE-4 (2, 10, and 50 mg/kg) for 2.5 months prior to sacrifice. There was a significant dose-dependent effect of HAE-4 on reducing insoluble A\(\beta\)40 and A\(\beta\)42 levels in the brain (Supplemental Figure 4).

Binding profile of HAE antibodies to lipidated apoE. Given that the antibodies were chronically injected into the peripheral compartment at high levels, we were somewhat surprised that HAE-1 and HAE-4 did not affect levels of plasma apoE or brain apoE, as apoE is abundant in both locations. This prompted us to ask whether some of the anti–apoE antibodies bound differentially to lipidated apoE versus other forms of the protein. In order to assess binding to lipidated apoE, we characterized the binding of HAE antibodies to plasma-derived apoE, the majority of which is lipidated. Plasma that contained intact plasma lipoproteins from apoE-KO (EKO), APOE2-, APOE3-, and APOE4-KI mice was
In contrast, plasma did not inhibit the binding of HAE-1 or HAE-4, suggesting that these antibodies do not bind lipidated forms of apoE (Figure 3E). The difference in ability to recognize plasma-derived apoE was further supported by the pharmacokinetic profiles of HAE-1, HAE-2, HAE-3, and HAE-4. Following i.p. injection (10 mg/kg) into APOE4 mice, HAE-2 and HAE-3 were rapidly cleared from plasma within 4 hours (Supplemental Figure 5), whereas HAE-4 was present in the plasma 14 days after injection at levels similar to a control mouse IgG2a antibody (Figure 3F). The likely target-mediated clearance observed with HAE-2 and HAE-3 suggests that these antibodies bind to plasma-derived lipidated apoE, which is abundant in the plasma (~50 μg/ml), whereas HAE-1 and HAE-4 do not. HAE-1 and HAE-4 appear to be selective for nonlipidated apoE, which is low or absent in plasma.

Binding of HAE-4 to plaque and aggregated apoE. Using unfixed frozen brain sections from APPPS1-21/APOE4 or APPPS1-21/EKO mice, we evaluated whether HAE-1 and HAE-4 could recognize apoE in the brain (Figure 4A). The presence of Aβ plaques was confirmed with anti-Aβ antibody HJ3.4 on sections from the same brain. Given the lower total signal seen by SPR for HAE-1 and HAE-4 compared with HAE-2 (Figure 3E), in contrast, plasma did not inhibit the binding of HAE-1 or HAE-4, suggesting that these antibodies do not bind lipidated forms of apoE.

Figure 4. HAE-1 and HAE-4 staining of amyloid plaques in unfixed mouse brain sections and specificity for heat-induced aggregates of apoE. (A) Unfixed frozen brain sections from APPPS1-21/APOE4 or APPPS1-21/EKO mice were stained with anti-Aβ antibody HJ3.4 and anti-apoE antibodies HAE-1 and HAE-4. Scale bar = 400 μm. (B) Binding of HAE-1, HAE-2, and HAE-4 to untreated recombinant apoE4 (untreated) or apoE4 that had been incubated at 40°C for 24 hours (40°C). (C) Incubation of apoE4 at 40°C for 24 hours results in the formation of aggregates recovered in the pellet fraction following ultracentrifugation at 186,000 g for 1 hour. Lane 1, untreated apoE4. Lane 2, apoE4 that had been incubated at 40°C for 24 hours. Supernatant (S) and pellet (P) from ultracentrifugation were resolved on SDS-PAGE and stained by Coomassie blue. (D) Binding of HAE-4 to different preparations of apoE4 immobilized at the same concentration (0.5 μg/ml) on the ELISA plate. Sup of untreated: supernatant fraction of untreated apoE4 from ultracentrifugation. Sup/Pel of 24 hours 40°C: supernatant/pellet fraction of apoE4 incubated at 40°C for 24 hours. (E) Binding of HAE-4 to untreated apoE4 and apoE4 that had been incubated at 40°C before and after denaturation by 1% SDS or 4 M guanidine HCl.
ure 1, E–G), we hypothesized that HAE-1 and HAE-4 bound to a less-abundant subspecies of the recombinant apoE4 that had been immobilized on the sensor chip. To assess whether HAE-4 binds to aggregated forms of apoE, we compared the binding of HAE-1, HAE-2, or HAE-4 to untreated apoE4 or apoE4 preincubated overnight at 40°C. HAE-2 bound to both forms of apoE similarly, whereas the binding of HAE-1 and HAE-4 to heat-treated apoE was dramatically enhanced (Figure 4B). HAE-1 preferentially binds to nonlipidated apoE4 and HAE-4 preferentially binds to nonlipidated apoE3 and apoE4. The binding preferences of HAE-1 to apoE4 and HAE-4 to apoE3 and apoE4 are retained with heat treatment (Supplemental Figure 6). In other words, HAE-1 and HAE-4 show strong preferential binding to aggregated apoE4, which may be the predominant form of apoE found in the plaques of APPPS1-21 mouse and human brain sections.

**Figure 5. Binding of HAE-1, HAE-4, and control antibody to human apoE4 in the brains of living mice.** (A) Control IgG2ab (n = 7), HAE-1 (n = 5), and HAE-4 (n = 6) conjugated with Alexa 594 were applied directly onto the surface of the brain in living APPPS1-21/APOE4 mice that were 6 months of age, and antibody localization was observed using 2-photon microscopy. Amyloid was labeled using methoxy-X04. The signal from Alexa 594 and methoxy-X04 was merged (MERGE) to show the colocalization of antibodies and plaques. (B) Control human IgG (n = 2) or chi–HAE-4 at 50 mg/kg body weight was injected i.p. in 1 dose (0 hour, n = 3) or 2 doses (0 and 48 hour, n = 3). APPPS1-21/APOE4 mice were sacrificed 48 hours after final injection. The antibodies in the brain were detected by biotinylated rabbit anti–human IgG followed by DAB. Left panel, bar = 1 mm. Right panel, high-power image of the indicated areas shown in the left panel; bar = 300 μm.

**Binding of HAE-4 to brain apoE in vivo.** Next, we tested whether HAE-1 and HAE-4 could bind to apoE in the brains of living mice. A mouse IgG2ab (control), HAE-1, and HAE-4 were conjugated with Alexa 594 and applied to the brain surface (40 μl of 1 mg/ml) of 6-month-old APPPS1-21/APOE4 mice. Antibody localization was monitored through a cranial window using 2-photon microscopy (Figure 5A). HAE-1 and HAE-4 were found to localize to amyloid plaques. To test whether peripherally administered apoE antibodies could enter the brain and bind to apoE in plaques, chi–HAE-4 or control human IgG were i.p. injected (50 mg/kg) for 1 or 2 doses into 5- to 6-month-old APPPS1-21/APOE4 mice. Two days after the final injection, chi–HAE-4 was detected bound to plaques in the dosed mice (Figure 5B). This indicated that chi–HAE-4 was able to enter the brain and bind to apoE in the Aβ plaques in living animals.

**The effects of HAE-1 and HAE-4 on microglial activation and Aβ deposition: requirement of a microglial response.** To determine whether HAE-1 and HAE-4 antibodies can increase activated microglia or infiltrating monocytes, we quantified CD45+ cells relative to the amount of fibrillar plaques after short-term treatment of HAE-1 and HAE-4 antibodies (4 doses by i.p. injection every 3 days) in 4-month-old APPPS1-21/APOE4 mice that already had existing plaques (Figure 6A and Supplemental Figure 7). After acute passive immunization, HAE-1 had no effect on the amount of CD45+ cells, whereas HAE-4 significantly increased the number of CD45+ cells compared with the controls (Figure 6A). Interestingly, there was no increase in the number of Iba-1+ cells around plaques following HAE-4 treatment ($1.02 \times 10^4 \pm 8.63 \times 10^2$ cells/μm² for...
control, n = 7 vs. 1.29 × 10^4 ± 2.09 × 10^3 cells/µm^2 for HAE-4, n = 7) suggesting that together with the CD45 data the total number of either microglia or infiltrating monocytes around plaques was not increased, but the cells present were in a more activated state. Although HAE-1 and HAE-4 can bind to apoE in plaques, antibody-driven plaque reduction may be dependent upon microglial activation. In order to assess whether microglia are required for an HAE-1– or HAE-4–dependent decrease in Aβ accumulation, we used AAV serotype 2/8 to drive the expression and secretion of full-length HAE-1 and HAE-4 antibodies with and without a D265A mutation in the Fc domain. The D265A mutation removes the effector function.

Figure 6. Reduction of plaques by HAE-1 and HAE-4 requires FcyR-mediated effector function. (A) At the age of 4 months, the APPPS1-21/APOE4 mice received 4 i.p. injections of 50 mg/kg of antibodies every 3 days. The mice were sacrificed 24 hours after the final injection and the fibrillar plaques were stained with X-34 and the activated microglia was stained with CD45. The ratio of percentage of area covered by CD45 staining/percentage of area covered by X-34 staining was quantified (equal numbers of male and female mice, n = 8–9/group). (B–E) APPPS1-21/APOE4 mice were injected at day P0 with AAV 2/8 into the lateral ventricle (equal numbers of male and female mice, n = 17–25/group). AAV 2/8 is able to express and secrete full-length HAE-1 and HAE-4 antibodies as well as the same constructs with a D265A mutation in the Fc domain (HAE-1Δ and HAE-4Δ). At the age of 3.5 months, the Aβ plaques (B) were stained with antibody HJ3.4, the fibrillar plaques were stained with X-34 (C), and the insoluble Aβ42 or Aβ40 (D) and Aβ42 (E) were measured by ELISA. One-way ANOVA followed by Tukey’s t test was performed to compare different groups shown in A–E. Data are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Discussion

In the present study, we report that both i.c.v. and i.p. administration of the anti-human apoE antibody HAE-4 (specific for apoE3 and apoE4) into APP transgenic mice expressing human apoE4 significantly reduced Aβ plaque load and Aβ accumulation in the brain. HAE-4 preferentially binds to nonlipidated forms of apoE as compared with lipidated apoE, which is the major form of apoE in vivo. When monomeric and aggregated forms of apoE were compared, HAE-4 preferentially bound to apoE aggregates. HAE-4 bound to apoE in amyloid plaques after direct application to the brain surface or after peripheral administration into living animals. Importantly, HAE-4 did not significantly alter the levels of total apoE in the brain or plasma, and both HAE-1 and HAE-4 were able to reduce plaque accumulation by direct central administration or expression via AAV. This effect appears to require microglial activation, as the corresponding antibodies with mutations in the Fc effector domain of the antibodies that ablate Fcγ receptor binding are not effective in plaque clearance. Overall, these findings demonstrate that certain anti-apoE antibodies selective for nonlipidated, aggregated apoE, such as HAE-1 and HAE-4, can preferentially bind to apoE in plaques and have very similar effects to anti-Aβ antibodies that also bind to and decrease Aβ accumula-
tion via a microglial-mediated clearance mechanism (18, 19). Further studies will be required to determine potential advantages and disadvantages to this approach versus the use of anti–Aβ antibodies as a treatment modality.

Although apoE has been established as the strongest genetic factor for LOAD for more than 20 years, the mechanism(s) by which apoE modifies AD pathogenesis is still not entirely clear. However, a large body of literature shows that apoE affects AD at least in part through exacerbating Aβ aggregation and reducing its clearance (7, 20, 21). The effects of apoE isoform, level, or lipidation status on Aβ pathology have been extensively studied in vitro and in vivo (7, 21). Whether increasing or decreasing of apoE function or expression is beneficial for reducing Aβ pathology has long been debated. Overexpression of apoE2 using viral vectors reduces Aβ pathology, whereas overexpression of apoE4 increases Aβ pathology in APP transgenic mice (22–25). Increasing apoE4 expression prior to but not after Aβ deposition enhances plaque burden (26). Genetic removal of endogenous murine apoE or reduction of apoE with antisense oligonucleotides prior to the onset of Aβ deposition decreases Aβ plaque load and fibrillar plaques in APP transgenic mice (27–29). Lowering apoE levels after Aβ deposition had started had no effect on Aβ levels (29). APP mice that express 1 copy of human apoE have markedly less Aβ pathology as compared with those expressing 2 copies of the same apoE isoform (30, 31). Blocking the interaction between apoE and Aβ using Aβ12-28p suppresses Aβ plaque deposition in APP transgenic mice (32). Taken together, only the overexpression of the apoE2 isoform appears beneficial, at least with respect to reducing Aβ accumulation. Based on the effects we describe, the ability to target specific pools of apoE might be an ideal therapeutic strategy to address the more than 60% of the patients with LOAD who are apoE4 carriers. Importantly, this approach of specifically targeting apoE in plaques allows for a direct antibody-mediated decrease in Aβ accumulation, in contrast to the alternate approach of simply lowering apoE levels. Whether anti–apoE antibodies such as HAE-4 will clear existing apoE-containing plaques will need to be tested in future studies.

In previous studies, we found that anti–mouse apoE antibody HJ6.3 reduced Aβ plaque load in APPPS1 mice expressing murine apoE (10, 11). In those studies, we were not able to determine the mechanism whereby anti-apoE modulated plaque pathology. To better explore this issue, as well as to develop antibodies that bind to human apoE, we generated a series of anti–human apoE antibodies and assessed their efficacy and mechanism of action in mice that develop Aβ deposition and express human apoE4. We focused most of these studies on antibody HAE-4, as it was most effective at reducing plaques when given peripherally. We first analyzed the apoE levels in the treated animals. Similar to the findings in our previous study using anti–mouse apoE antibody HJ6.3 (10, 11), peripheral administration of HAE-4 did not change the level of plasma apoE or the level of total brain apoE in the tissue lysates. Therefore, the effects of HAE-4 on Aβ plaques were not mediated simply by lowering total apoE levels. It was previously reported that a plaque-specific Aβ antibody (mE8) that targets only pyro-glutamated Aβ, a small proportion of Aβ in amyloid plaques, was able to localize to Aβ plaques and remove them by triggering microglia-mediated phagocytosis (19). In the present study, we found that HAE-4 is able to bind to apoE in amyloid plaques, both on unfixed brain sections and in the brain of living APPPS1-21/APOE4 mice following central or peripheral injection. Further, we found that the ability of HAE-4 to decrease plaque accumulation was dependent on microglial activation. This suggests that the key features of this antibody’s ability to decrease Aβ plaques are its selectivity toward binding a conformation of apoE in amyloid plaques, specifically apoE aggregates, and its ability to direct microglial-driven apoE-amyloid phagocytosis.

To better understand whether the antibody most effective at decreasing plaques was binding to a particular form of apoE that was selectively present in plaques and not normally found in brain or blood, we assessed the binding affinity of HAE-4 to lipoprotein-free nonlipidated apoE as well as monomeric versus aggregated apoE. We found that HAE-4 preferentially interacts with a nonlipidated form of apoE as compared with lipidated forms that would be present in plasma, cerebrospinal fluid, or the extracellular space of the brain. This is the first report to our knowledge that suggests that targeting a specific conformational form of apoE reduces Aβ pathology in APP transgenic mice. Given that nonlipidated apoE is only a small percentage of total apoE in vivo (33), targeting this pool of apoE may underlie the lack of effect on apoE levels or lipid metabolism. Reduced binding to lipidated apoE contributes to the much longer plasma half-life of HAE-4 as compared with HAE-2 and HAE-3, which strongly bind lipidated apoE (Figure 3F, Supplementary Figure 5). A longer half-life greatly increases both peripheral and brain exposure of the antibody and enables increased plaque decoration.

Previous work has shown that decreasing Aβ pathology by enhancing apoE lipoprotein via ATP-binding cassette transporter A1 (ABCA1) has beneficial effects (34–36), and that decreasing apoE lipoprotein increases Aβ pathology (37). It is possible that poorly lipidated apoE adopts a conformation more prone to aggregation and thus promotes Aβ aggregation. In the present study, we demonstrated that a potent, plaque-reducing antibody may recognize this form of aggregated apoE, which resides in Aβ plaques in APPPS1-21/APOE4 mice. In the future, the frequency and abundance of HAE-4 immunoreactivity apoE in the brain of patients with AD will need to be determined.

We found that the effects of 2 different anti–apoE antibodies appear to require microglial-mediated Aβ phagocytosis, because versions of HAE-1 and HAE-4 lacking a functional Fc domain of the antibody were not able to decrease Aβ deposition. In addition, in APPPS1-21/APOE4 mice that already had plaques, HAE-4 acute administration substantially increased CD45+ cells around plaques. A variety of anti–Aβ antibodies have been studied for their ability to decrease Aβ plaques both in animal models and in humans. The antibodies shown to have the greatest effects on Aβ deposition appear to work by binding certain Aβ species in plaques and then facilitating clearance via microglial phagocytosis (18, 19). The mechanism we demonstrate here for HAE-1 and HAE-4 appears similar, except that these antibodies bind to an Aβ-binding molecule (i.e., apoE) and not directly to Aβ itself. The effects we see with these antibodies appear similar to that seen with Aβ antibodies that lower plaques. Whether the CD45+ reactive cells are microglia or infiltrating monocytes and to what extent FcR expressed by other cell types in the brain contribute
to the process of decreasing Aβ accumulation needs to be sorted out in future studies. In addition to efficacy, it will be important to determine whether anti–apoE antibodies with features such as HAE-4 have any potential side effects. We were not able to determine whether there was an increase in microhemorrhages in the APPPS1-21/APOE4 mice following treatment with HAE-4, as there was very little amyloid angiopathy in this mouse model. Future studies addressing this issue may support the development of anti–apoE antibodies for the treatment of AD.

Methods

Animals. APPPS1-21 mice on a C57BL/6J background (gift from Mathias Jucker, Hertie Institute for Clinical Brain Research, Tübingen, Germany) coexpress human APP with a Swedish mutation (KM670/671NL) and mutant PS1 with the L1669 mutation under control of a Thy1 promoter (13). APOE2-, APOE3-, and APOE4-knock-in mice express APOE E2, E3, and E4 under control of the endogenous mouse regulatory elements on a C57BL/6J background (38). EKO plaque pathology in APPPS1-21/APOE4 mice begins at the age of 2 months.

Generation of antibodies. The HAE antibodies were generated by injecting recombinant apoE4 with complete Freund’s adjuvant into mice. For an initial screening of antibodies, supernatants from hybridoma cells were added to 96-well plates coated with recombinant apoE4 and the HAE that bound to apoE4 was detected using anti–mouse IgG antibodies at serial concentrations (starting at 300 nM). Bound HAE antibodies were detected in-house (10) was used as the detecting antibody. Recombinant apoE4 was coated on the chip to reach 550 RU (HAE-1 and HAE-4) or 280 RU (HAE-2). A range of serially diluted antibodies (1.2 nM-100 nM for HAE-2; 12 nM-1,000 nM for HAE-1 and HAE-4) was injected at a flow rate of 30 μl/min, and sensorgrams were fitted using the 1:1 Langmuir model.

Intracerebroventricular antibody administration and sample collection. At the age of 2 months, APPPS1-21/APOE4 mice underwent surgical implantation of a subcutaneous osmotic minipump (Alzet, model 2106) connected to a catheter into the left lateral cerebral ventricle (Bregma -0.4 mm, 1.0 mm lateral to midline, 2.5 mm below the skull). The apoE antibodies or control antibodies (2 mg/ml) were filled into the osmotic minipump and continuously infused (i.c.v.) at the speed of 0.15 μl/h for 6 weeks. At the age of 3.5 months, the mice were perfused with ice-cold PBS containing 0.3% heparin. The right hemibrain was dissected and flash-frozen on dry ice for biochemistry assays. The left hemibrain was fixed in 4% paraformaldehyde for histological analysis. Serial coronal sections at 50-μm thickness were collected from the rostral to the caudal end of each brain hemisphere using a freezing sliding microtome (Leica Biosystems).

Intraperitoneal antibody administration and sample collection. Two-month-old female APPPS1-21/APOE4 mice were injected i.p. with a weekly dose of 50 mg/kg body weight of control or HAE anti–apoE antibodies for 7 doses. At the age of 3.5 months, the mice were perfused with ice-cold PBS containing 0.3% heparin. The right hemibrain was dissected and flash-frozen on dry ice for biochemical assays for Aβ and apoE. The left hemibrain was fixed in 4% paraformaldehyde for 48 hours for histological analysis of amyloid plaque load. The fixed brains were sectioned by Multibrain Technology (NeuroScience Associates NSA Labs) at a 50-μm thickness. For the dose-response study of HAE-4, another cohort of APPPS1-21/APOE4 mice received weekly i.p. injections of HAE-4 (2 mg/kg, 5 mg/kg, and 10 mg/kg), anti–Aβ HJ3.4 (50 mg/kg), or IgG2ab (50 mg/kg). The cortices were extracted sequentially in PBS and 5 M guanidine and the Aβ42 and Aβ40 in the guanidine fraction was assessed using ELISA.

ELISA for tissue lysates. To extract Aβ in different fractions, brain cortices were sequentially homogenized with cold PBS, 1% Triton-X 100, and 5 M guanidine buffer in the presence of 1 mM protease inhibitor mixture (Roche). The levels of Aβ1-40, Aβ1-42, and apoE were measured by sandwich ELISA. For Aβ1-40 or Aβ1-42, anti–Aβ1-40, anti–Aβ1-42 (produced in-house) or anti–Aβ1-40, HJ7.4 (produced in-house) were used as capture antibodies, and anti–Aβ1-42, HJ5.1-biotin (produced in-house) was used as a detecting antibody (39). For apoE ELISA, HJ1.62 (produced in-house) (10) was used as the capture antibody and HJ6.1-biotin (produced in-house) (10) was used as the detecting antibody. Recombinant apoE4 was used as the standard for the apoE ELISA. For assessment of the concentration of rHAE-1, rHAE-1a, rHAE-4, and rHAE-4\(\Delta\) following expression via AAV2/8, recombinant apoE4 was coated on 96-well ELISA plates overnight at 4°C. After washing, individual puri-
Binding of HAE antibodies to lipidated apoE. Blood was collected from the right atrium of 6-week-old, apoE-targeted replacement mice or EKO mice and centrifuged in plasma collection tubes (containing EDTA) at 14,000 g for 5 minutes. For the plasma-coat ELISA, plasma was diluted 50-fold in PBS and coated to the bottom of half-well ELISA plates overnight at 4°C. Plates were washed with PBS and blocked in 5% BSA-PBS for 2 hours. Antibodies were serially diluted 5-fold (starting at 500 nM) in 5% BSA-PBS and incubated for 1 hour at room temperature with shaking (500 rpm). Plates were next washed extensively in PBS and bound antibody was detected with an HRP-goat anti-human secondary antibody (catalog 115-035-003, Jackson ImmunoResearch Laboratories) and TMB were extensively in PBS and the captured apoE was detected with polyclonal antibody /plasma solutions were added to the blocked plates for 1 hour at 37°C. Plates were washed with PBS and blocked in 4% milk-PBS for 2 hours. Antibodies were serially diluted 5-fold (starting at 500 nM) in 5% BSA-PBS and incubated for 1 hour at room temperature with shaking (500 rpm). Plates were next washed extensively in PBS and captured apoE was detected with polyclonal antibody (catalog 178479, Millipore). Anti-goat HRP (catalog 705-035-147, Jackson ImmunoResearch Laboratories) and TMB were used as the chromogenic reagent and reactions were stopped with BioFX stop solution. Plates were read at OD 650. Replicate assays were performed and data from 1 experiment in duplicate are shown.

Pharmacokinetics of HAE antibodies in mice. Murine HAE-4 and control mouse Ig2a anti-HER2 were injected i.p. at 2 mg/kg, 10 mg/kg, and 50 mg/kg, and plasma samples were collected by submandibular puncture at various time points. Assessment of plasma antibody concentrations was performed using coated recombinant apoE4 (5 μg/ml) to capture dosed HAE-4, and recombinant Her2 protein (R&D) (1 μg/ml) to capture the control antibody. Plates were blocked with 3% BSA in TBS/0.1% Tween for 1 hour and washed 3 times before incubation with plasma samples at a 1:2500 dilution. Bound antibodies were detected with HRP-anti-mouse IgG (catalog 115-035-003, Jackson ImmunoResearch Laboratories). The standard curve range was 0.49–1000 ng/ml and fit with a 4-parameter logistic function.

Binding of HAE-1 and HAE-4 to apoE in the unfixed brain tissue. Brain tissue from APPPS1/2E4 mice was sectioned at 20-μm thickness using a cryotome (ULTRApro 5000, Vibratome) and mounted on slides. The sections were stained with biotinylated HJ3.4, HAE-1, or HAE-4. The antibodies bound to the sections were detected using an ABC kit (Vector Laboratories) followed by DAB (Sigma-Aldrich).

Cranial window implantation, topical application of antibodies and multiphoton imaging. APPPS1/2E4 mice (5–7 months old) were anesthetized under 1.5% isoflurane, and a 4-mm cranial window was drilled in order to expose the cortex, as previously described (24). After removing the dura mater, 40 μl of each antibody stock (1.0 mg/ml), previously conjugated with Alexa 594 (Alexa Fluor 568 Antibody Labeling Kit, ThermoFisher Scientific), was topically applied for 30 minutes. After 2 washes with sterile PBS, a glass coverslip was cemented on the skull in order to seal the window before imaging. Fluorescein dextran (70,000 Da; 12.5 mg/ml in sterile PBS; Invitrogen) was also injected retroorbitally to provide a fluorescent angiogram. After a first set of images was taken in order to detect the signal from each antibody alone, methoxy-XO4 (5 mg/kg) was injected intravenously in order to label amyloid plaques as well as cerebral amyloid angiopathy, as previously described (40). In vivo multiphoton imaging was performed using an Olympus Fluoview FV1000MPE multiphoton laser-scanning system mounted on an Olympus BX61WI microscope and an Olympus ×25 objective (numerical aperture = 1.05). A DeepSee Mai Tai Ti: sapphire mode-locked laser (Mai Tai; Spectra-Physics) generated 2-photon excitation at 800 nm, and detectors containing 3 photomultiplier tubes (Hamamatsu) collected emitted light in the range of 420–460 nm, 495–540 nm, and 575–630 nm. Mice were placed on the microscope stage, heated using a heating pad, and feedback regulation was obtained from a rectal temperature probe (Harvard Apparatus). Z-series images (2 μm steps, depth of ~200 μm, 512 × 512 pixels) were taken to cover a large surface of the window. The laser power was measured and adjusted before each imaging and the settings of the photomultiplier tubes were unchanged throughout the different imaging sessions and between all antibodies applied.

Binding of peripherally administered chi-HAE-4 to apoE in the brain. Chi-HAE-4 and control human IgG were injected i.p. at 100 mg/kg into 4- to 6-month-old APPPS1/2E4 mice for 1 (0 hour) or 2 (0 and 48 hours) doses and the mice were sacrificed 48 hours after the final injection. The antibodies were detected using biotinylated rabbit anti-human IgG (catalog ab97158, Abcam) followed by DAB.
Acute injection of HAE antibodies and microglial activation staining. APPPS1-21/APOE4 mice received 4 doses of antibodies every 3 days at the age of 4 months. Each dose was 50 mg/kg (administered i.p.). The mice were sacrificed 24 hours after final injection. The fibrillar plaques were stained using X-34. Activated microglia were immunostained using rat-anti CD45 (catalog MCA1388, BioRad) followed by biotinylated goat anti-rat IgG secondary antibody (catalog A10517, Life Technologies). Iba-1 cells were detected using rabbit anti-Iba-1 (catalog 019-19741, Wako) followed by donkey anti–rabbit IgG Alexa Fluor 647 (catalog A-31573, ThermoFisher Scientific). For quantification, 3 Z-stack images were captured per animal on the Nikon A1R’ confocal microscope using ×20 objective at 1024 × 1024 pixel resolution with a Z-step size of 1.1 μm at 32-μm thickness. These images were then processed using Imaris (Bitplane). The coordinates of X-34+ plaques and Iba-1+ microglia were determined using the Spots function and imported into Matlab (Mathworks). An automated script was used to determine the microglial density around plaque surfaces, and the number of microglia within a 30 μm radius was calculated.

Preparation and injection of AAV8 vectors expressing control antibody and HAE antibodies. The variable regions of heavy and light chain cDNA sequences of control IgG, HAE-1, and HAE-4 were cloned from hybridoma cells. The single open reading frame (ORF) of the heavy chain, Furin cleavage site, P2A, and the light chain was assembled into polymerase chain reaction. All antibody subtypes were switched to mouse IgG2a. The assembled single ORF was inserted into AAV-expressing vector (serotype 2) with a chicken β actin promotor. The D265A mutation on the CH2 region was generated by QuikChange (Agilent Technologies) site-directed mutagenesis. AAV vectors were prepared at Hope Center Viral Vector Core with serotype 8 helper vectors. On P0, APPPS1-21/APOE4 mice (mixed sexual phenotype, n = 17–25/group) received a bilateral i.c.v. injection of 2 μL AAV vector (1.0 × 1014 vg/mL). The mice were sacrificed at 3.5 months of age. After perfusion with PBS, one brain hemisphere was immersion fixed in 4% paraformaldehyde for further histological analysis and the other hemisphere was dissected for further biochemical analysis. For histological analysis, 3-μm sections were processed using X-34. The cortices were sequentially extracted using PBS and 5 M guanidine, and Aβ1-40 and Aβ1-42 were measured by ELISA. The concentration of antibodies in the PBS fraction was also measured by ELISA.

Statistics. Two-tailed Student’s t test was used to determine whether there were significant differences between 2 groups unless otherwise specified. One-way ANOVA was used to compare differences among 3 or more groups, followed by Tukey’s s test unless otherwise specified. Data in all the figures are mean ± SEM unless otherwise specified. P < 0.05 was considered significant.

Study approval. All animal experimental protocols were approved by the Animal Studies Committee at Washington University.

Author contributions
FL, AL, YZ, APS, JLG, CEGL, GG, NBL, RJW, JDU, PMS, EH, KH, ZKS, MSD, BTH, and DMH designed the research studies. HJ, FL, AL, YZ, APS, NBL, JG, MSD, RJW, and DMH generated and characterized the anti–apoE antibodies. FL, AL, MX, HJ, MBF, RH, KBL, JK, GOR, YZ, JRS, APS, JLG, EPL, and EH conducted experiments and acquired data. FL, AL, MX, YZ, APS, JLG, NBL, RJW, EPL, EH, JG, KH, MSD, ZKS, BTH, and DMH analyzed the data. FL, AL, YZ, APS, JLG, NBL, MSD, EH, BTH, RJW, and DMH wrote the manuscript.

Acknowledgments
This work was supported by a research grant from Denali (to DMH), the NIH (AG R01 AG047644 to DMH and BTH, and grants P50 AG05681, P01 AG03991, and P01 AG026276), and the BrightFocus Foundation (A2013037F to FL). The authors acknowledge Maya Leabman (independent scientific consultant) for discussions on pharmacokinetics, Katherine Jenkins (Denali) for animal support, and Wilbur Song and Marco Colonna (Washington University) for the methods of Iba-1 immunostaining quantification.

Address correspondence to: David M. Holtzman, Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, 660 S. Euclid Avenue, Box 8111, St. Louis, Missouri 63110, USA. Phone: 314.747.0644; Email: holtzman@neuro.wustl.edu.


RESEARCH ARTICLE

The Journal of Clinical Investigation

2015

jci.org Volume 128 Number 5 May 2018